3.07
+0.03
(0.99%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 3.04 - 3.09 |
| 52 week | 2.93 - 8.18 |
| Open | 3.05 |
| Vol / Avg. | 0.00/239,657.00 |
| Mkt cap | 25.89M |
| P/E | - |
| Div/yield | - |
| EPS | -1.71 |
| Shares | 8.43M |
| Beta | 1.99 |
| Inst. own | 26% |
Events
May 13, 2013
Q1 2013 Cyclacel Pharmaceuticals, Inc. Earnings Conference Call
Apr 30, 2013
Cyclacel Pharmaceuticals, Inc. at Needham Healthcare Conference
Mar 27, 2013
Q4 2012 Cyclacel Pharmaceuticals, Inc. Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | -8297.37% | -2180.69% |
| Operating margin | -9268.42% | -2344.49% |
| EBITD margin | - | -2310.01% |
| Return on average assets | -59.76% | -53.06% |
| Return on average equity | -94.59% | -71.91% |
| Employees | 18 | - |
| Carbon Disclosure Rating | - | - |
Address
#1500, 200 Connell Drive
BERKELEY HEIGHTS, NJ 07922
United States - Map
+1-908-5177330 (Phone)
+1-866-2713466 (Fax)
BERKELEY HEIGHTS, NJ 07922
United States - Map
+1-908-5177330 (Phone)
+1-866-2713466 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the immune system to treat cancer and other serious illnesses. The Company develops proprietary techniques of antibody engineering to develop antibody-based products for the applications in immunology, oncology, and infectious diseases. Xcyte Therapies is currently conducting Phase I/II clinical trials in hormone-refractory prostate cancer, multiple myeloma and chronic lymphocytic leukemia.
Officers and directors
| David C. U'Prichard Ph.D. | Independent Chairman of the Board | |
| Spiro Rombotis | President, Chief Executive Officer, Director | |
| Christopher S. Henney Ph.D. | Independent Vice Chairman of the Board | |
| Paul McBarron | Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director | |
| Judy H Chiao M.D. | Vice President - Clinical Development and Regulatory Affairs | |
| Nicholas G. Bacopoulos Ph.D. | Independent Director | |
| John Banham | Independent Director | |
| Gregory T. Hradsky | Independent Director | |
| Lloyd M. Sems | Independent Director |